Evan Castiglia
Partner @ Thuja Capital
Amsterdam, The Netherlands
Evan Castiglia is a Partner of Thuja Capital.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Evan Castiglia invests in
Stages Evan Castiglia invests in
Countries Evan Castiglia invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 2 (67%)
- Health Care 1 (33%)
- Life Science 1 (33%)
- Therapeutics 1 (33%)
- Medical Device 1 (33%)
Stage
- Seed 1 (33%)
- Series A 1 (33%)
Country
- France 1 (33%)
- Germany 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Tacalyx
|
Tacalyx develops therapeutics targeting cancer-specific carbohydrate antigens on the surface of metastatic malignant tumors where no satisfactory treatments exist.The name Tacalyx is derived from TACA (Tumor Associated Carbohydrate Antigen) and ‘lyx’ from the term Glycocalyx, the glycan-containing layer covering cells. Cancer cells differ fromnormal cells by displaying aberrant carbohydrate structures on their surfaces promoting metastasis, angiogenesis or suppression of the immune system. TACAs result from the aberrant glycosylation that is seen with transformation to a tumor cell and represent attractive targets for cancer treatment since they are displayed with high cancer specificity and enhance tumor virulence via the mentioned diverse mechanisms. | $12.9M / Seed / Apr 29, 2026 | |
|
Tacalyx
|
Tacalyx develops therapeutics targeting cancer-specific carbohydrate antigens on the surface of metastatic malignant tumors where no satisfactory treatments exist.The name Tacalyx is derived from TACA (Tumor Associated Carbohydrate Antigen) and ‘lyx’ from the term Glycocalyx, the glycan-containing layer covering cells. Cancer cells differ fromnormal cells by displaying aberrant carbohydrate structures on their surfaces promoting metastasis, angiogenesis or suppression of the immune system. TACAs result from the aberrant glycosylation that is seen with transformation to a tumor cell and represent attractive targets for cancer treatment since they are displayed with high cancer specificity and enhance tumor virulence via the mentioned diverse mechanisms. | $7.5M / Seed / Jun 11, 2024 | |
Gradient Denervation Technologies
|
Gradient Denervation Technologies develops a medical device for a transvascular treatment of pulmonary hypertension, based on prior research and intellectual property developed at Stanford University. | $15M / Series A / Sep 07, 2023 |
Co-Investors
About Thuja Capital
Thuja Capital invests in early stage medical product innovations for diagnosis, cure, care or prevention.
Thuja Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Michel Briejer
Managing Partner
|
|||
|
Evan Castiglia
Partner
|
|||
Florian Ludwig
Venture Partner
|
|||
|
Harrold van Barlingen
Founder and Managing Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Evan Castiglia invest in?
Evan Castiglia invests primarily in Biotechnology, Health Care and Life Science startups, most often at Seed and Series A stage. Most of the 3 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Evan Castiglia?
Public channels for Evan Castiglia include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Evan Castiglia last invest?
The most recent investment recorded for Evan Castiglia closed in Apr 2026. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
